RedHill Biopharma Ltd., known by its ticker symbol RDHL, is a specialty biopharmaceutical company. It was founded in 2009 and is headquartered in Tel Aviv, Israel, with a US office in Raleigh, North Carolina. The biopharmaceutical company operates internationally and is listed on both the NASDAQ Global Market and the Tel Aviv Stock Exchange.
The main aim of RedHill Biopharma Ltd. is the development, manufacturing, and commercialization of proprietary drugs for several therapeutic indications. They focus primarily on diseases with high unmet medical needs, particularly in the fields of gastrointestinal and infectious diseases. The company's strategic approach to drug development is to bring novel, small molecule compounds to the market by leveraging its development capabilities and expertise in these areas.
RedHill Biopharma Ltd's rich and expanding portfolio includes multiple late-stage clinical programs. This portfolio covers numerous drugs, some of which are wholly owned and some of which are collaborations with other pharmaceutical companies. Some of its key products include Talicia (RHB-105) for the treatment of Helicobacter pylori infection, Movantik for opioid-induced constipation, and RHB-204 for pulmonary non-tuberculous mycobacteria (NTM) infections.
Talicia is the first and only FDA-approved rifabutin-based therapy for H. pylori infection. The approval of Talicia by the FDA in 2019, marked a significant milestone for RedHill as it positioned the company at the front line of fighting antibiotic resistance.
RedHill’s strategy also includes collaborations, acquisitions, and in-licensing in the discovery, development, and, in some cases, the commercialization stages of its therapeutic candidates. The company works closely with hospitals, university research centers, and other institutions around the world to accelerate its drug development initiatives and deliver innovative treatments to patients.
In addition to its focus on gastrointestinal and infectious diseases, RedHill has also been active in responding to the COVID-19 pandemic. They are currently advancing OPAGANIB (Yeliva, ABC294640), a first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with anticancer, anti-viral, and anti-inflammatory activities, in global Phase 2/3 and Phase 2 studies in patients with severe COVID-19 pneumonia.
RedHill Biopharma Ltd. continues to grow steadily, signifying its commitment to research and development in areas where there is a pressing need for new treatments. The range of their pipeline, from early development stages to late-stage clinical programs, illustrates a future-forward approach and commitment to innovation in biopharmaceutical research.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
RedHill Biopharma Ltd. (RDHL) has acquired exclusive global commercialization rights to Rebyota and U.S. rights to Clenpiq from Ferring Pharmaceuticals for a $12 million upfront payment. The deal includes tiered royalties and sales milestones, with RedHill taking on commercialization while Ferring continues manufacturing. The acquisition aims to broaden RedHill's gastrointestinal portfolio and leverage existing sales infrastructure, though the ultimate financial benefit depends on sales growth and managing royalty and inventory costs.
Redhill Biopharma Ltd. (RDHL) stock experienced extreme volatility, closing at $1.07 after swinging between $1.01 and $1.60 on heavy volume, indicating an overbought condition and potential exhaustion. While the daily chart shows a structurally bullish trend, momentum indicators like RSI and Bollinger Bands suggest the stock is stretched, increasing mean-reversion risk. The article advises caution, highlighting key support and resistance levels, and noting that further upside may require a consolidation phase due to extreme overbought readings.
RedHill Biopharma's shares surged by as much as 58.85% to a morning high of $1.60 after the company announced it divested its 70% stake in the Talicia gastrointestinal business to a subsidiary of Apotex Health Corp. for an upfront payment of $18 million. The deal also includes up to an additional $35 million in potential net-sales-milestone payments, providing RedHill with immediate capital and funding for its commercial GI business expansion. CEO Dror Ben-Asher stated this transaction significantly strengthens RedHill's liquidity and supports its path toward operational profitability.
RedHill Biopharma's stock surged 66.4% after announcing the sale of its 70% stake in the Talicia business to Apotex for $18 million upfront cash and up to $35 million in potential milestone payments. This cash infusion is expected to improve liquidity and fund commercial expansion, moving the micro-cap biotech closer to profitability. Insider trading activity for RDHL over the past six months shows two sales by the Chief Operating Officer.
RedHill Biopharma (NASDAQ:RDHL) is scheduled to report financial results today, placing scrutiny on its commercial execution, development programs, funding, and balance sheet. The article emphasizes that company-specific operational evidence regarding clinical and commercial progress, patient access, and cash discipline is more crucial than broad market assumptions. Readers should focus on qualitative signals like customer decisions, inventory movement, and alignment of capacity with demand to assess the company's real progress.